Author:
Martinez Jorge Luis Dominguez,Fundora Rodolfo Arozarena,Barbosa Ivette Arozarena,Barbosa Odette Arozarena
Publisher
Springer Nature Switzerland
Reference39 articles.
1. Aljuhani, O., Korayem, G. B., Altebainawi, A. F., Alotaibi, M. S., Alrakban, N. A., Ghoneim, R. H., Vishwakarma, R., Al Shaya, A. I., Al Harbi, S., Gramish, J., Almutairi, D. M., Alqannam, G., Alamri, F. F., Alharthi, A. F., Alfaifi, M., Al Amer, A., Alenazi, A. A., Bin Aydan, N., Alalawi, M., & Al Sulaiman, K. (2023). The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study. Saudi Pharmaceutical Journal, 31(7), 1210–1218. https://doi.org/10.1016/j.jsps.2023.05.006
2. Burki, T. (2021). Behind Cuba’s successful pandemic response. The Lancet Infectious Diseases, 21(4), 465–466. https://doi.org/10.1016/S1473-3099(21)00159-6
3. Castellanos-Serra, L. (2020). Bringing Cuban Biotech Research to bear on COVID-19: All hands and minds on deck. MEDICC Review, 22(2), 31. https://doi.org/10.37757/MR2020.V22.N2.9
4. Centre for State Control of Medicines, Equipment and Medical Devices. (2014, January 6). Heberón® Alfa1 (Interferón alfa 2b hu-rec). Resumen de las características del producto. https://www.cecmed.cu/file/1336/download?token=qem7Z7fY
5. Centre for State Control of Medicines, Equipment and Medical Devices. (2018, March 7). Heparina Sódica. Resumen de las características del producto. https://www.cecmed.cu/file/6117/download?token=WjO7o9Nh